Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
Date:8/8/2011

THE WOODLANDS, Texas, Aug. 8, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.  

Progress in Clinical Pipeline

  • Lexicon commenced a Phase 2b clinical trial for LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2.  The company also presented data at the 71st Scientific Sessions of the American Diabetes Association from a mechanistic study designed to investigate the effect of LX4211 on peptide hormones in the intestinal tract in patients with type 2 diabetes.  The data from the study demonstrated that a single dose of LX4211 significantly increased GLP-1 (total and active) and PYY, important mediators of glycemic and appetite control.  
  • Lexicon successfully completed a Phase 1 study of LX1033, a serotonin synthesis inhibitor being developed as a potential treatment for irritable bowel syndrome (IBS).  Results from the study demonstrated that LX1033 was well tolerated at all doses and produced a statistically significant reduction in serotonin synthesis compared to placebo, as measured by both plasma (p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin synthesis.  Importantly, a greater reduction in serotonin synthesis was achieved with lower and less frequent dosing than was observed with Lexicon's first generation serotonin synthesis inhibitor, LX1031, which had previously demonstrated improvements in global assessment of adequate relief and
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    2. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    3. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    4. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
    5. Lexicon to Provide First Quarter 2011 Financial Results
    6. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    7. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    9. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    10. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    11. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/56cq5n/motion_simulation ) has ... Market by Type (Hydraulic and Actuator), Degree of ... Application (Automotive, Defense, Entertainment, Healthcare, Mining, R&D, Sports, ... " report to their offering. ... enough for commercial use, and thus its market ...
    (Date:6/2/2015)...  Nektar Therapeutics (NASDAQ: NKTR ) and The ... a research collaboration that includes a Phase 1/2 clinical ... preferentially stimulate production of CD8-positive T cells, which are ... which is also known as the Interleukin-2 receptor beta ... to increase proliferation of these effector T cells. 1 ...
    (Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
    Breaking Medicine Technology:Global Motion Simulation Market 2015-2020 - Type, Degree of Freedom, Application, and Regional Analysis 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2
    ... Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a ... company will actively participate at the Save A Leg, ... in Orlando tomorrow, October 8. , In addition to exhibiting its ... a workshop entitled " The ...
    ... ACCESS PHARMACEUTICALS, INC . (OTC ... agreement with iMedicor (OTC Bulletin Board: VMCI) for the North ... rinse for the management of oral mucositis and stomatitis caused ... System application, initial introduction of MuGard to the 216,000 selected ...
    Cached Medicine Technology:Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 2Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 2Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 4
    (Date:6/2/2015)... Campbell, California (PRWEB) June 02, 2015 ... society, announced a study from the RSSearch® Patient ... of stereotactic body radiotherapy (SBRT) for the treatment ... (NSCLC) or lung metastases. , The study, ... Oncology ( http://www.ro-journal.com/content/10/1/113/abstract ), included 111 patients with ...
    (Date:6/2/2015)... Robert LaPrade, MD, PhD, ... Steadman Philippon Research Institute, participated in the study “ ... Specialization? ” This was a collaborative project from the ... that was recently published in the American Journal of ... limited, there is evidence that early sport specialization may ...
    (Date:6/2/2015)... Each year, Cosmetic Executive Women (CEW) ... This year, the organization’s members – 8,000 industry experts ... QVC® Beauty Quest Award at the 2015 Beauty Insiders’ ... Technology and 2-in-1 approach to skincare differentiated it amongst ... loyal consumer and professional fan bases, QVC has awarded ...
    (Date:6/2/2015)... June 02, 2015 SB 277 (CA ... for children to attend public or private school. SB277 ... but bypassed the Appropriations Committee (Sacramento Bee, May 11, ... contentious hearings. , “We believe that this bill ... (PBEs) more than it will (the) affect public health ...
    (Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Miriam Wirski as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to present Miriam with this prestigious honor,” said NAPW ...
    Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
    ... 22 Atlas Spine, Inc., a spinal,technology development ... announced today the national launch of the STATURE ... radiolucent MIS compatible spacer,system designed to utilize a ... the thoracic and lumbar spine., "After significant ...
    ... Its Summer-Long Harley-Davidson ... Celebration Promotion, MILWAUKEE, May 22 Miller Brewing Company ... every Miller Lite,bottle cap collected now through Sept. 1, 2008, ... the "ultimate light beer,",is the official beer sponsor of this ...
    ... The Foundation of the National Student Nurses Association ... Jersey Regional Faculty Fellowships to two Rutgers College of ... The fellowship will help Ho-Shing, a Union, N.J. resident, ... academic fees, and book expenses during the Fall 2008 ...
    ... Providing Real Parental Reassurance, NEW YORK, May ... developer of biosensor and microprocessor technologies for,use in ... trials for its latest homecare wellness product using ... the traditional home baby,monitor market., Each year, ...
    ... $4 MILLION INVESTMENT WILL SUPPORT AMERICA,S NEW GENERATION ... The National,Alliance for Hispanic Health (the Alliance) announced ... a new,partnership improving Hispanic student access to higher ... (STEM). The Program is,made possible through a $4 ...
    ... Global Reach of Novel Technology, N. BILLERICA, ... measurement of cellular bioenergetics, announced today,that Primetech Corporation ... and consumables in Japan., "Japan,s contribution to ... we have seen with the recent acquisition of ...
    Cached Medicine News:Health News:Atlas Spine Launches Stature(TM) Vertebral Body Replacement System 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 3Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2
    Straight shafts with teeth and 5 mm tying platform. Wide serrated handle with polished finish. Teeth: 0.3 mm. Manufactured in titanium....
    Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish....
    Ergotec Vetriretinal Instrument System. Fine angled tips (3 mm). 20 gauge shaft length with black tip. Overall length from rear rotation knob to tip....
    Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
    Medicine Products: